Executive Management

Lisa Anson

Chief Executive Officer

Experience General Manager, former President of AstraZeneca UK

Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.

Lisa had previously been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager.

Lisa has also been President of the Association of the British Pharmaceutical Industry (ABPI), a position from which she stepped down in 2018. She was a Board member of the ABPI from 2012 during which time she has chaired a number of UK industry committee’s and worked closely with the UK Government. In 2018 she was elected to the Board of the Bio Industry Association (BIA).

Lisa currently lives in Cheshire with her husband Andy and her three children.

Dr James Mead

Chief Financial Officer

Previously CFO of AstraZeneca Netherlands, with wide sector experience

James was appointed on 1st February 2019. James has held a variety of highly relevant Finance leadership roles over a 16 year career with AstraZeneca Plc. As Chief Financial Officer of AstraZeneca Netherlands – a $200 million turnover business – he was a core member of a management team accountable for delivery of stretching annual P&L targets and other balanced scorecard objectives during a period of significant change. As R&D Portfolio Finance Director he was responsible for financial analysis of the entire R&D portfolio in order to support decision-making at the CEO-chaired AZ Portfolio Investment Board. He has been the Finance Director of multiple clinical development project teams, guiding assessment of the valuation impact of key decisions such as clinical trial design, commercial launch strategy and product lifecycle management. Additionally, James has gained capital markets experience through positions in AstraZeneca’s Investor Relations and Corporate Finance teams. James holds a PhD in Molecular Biology and a First Class honours degree in Biochemistry, both awarded by Cardiff University. He is also an Associate Member of the Chartered Institute of Management Accountants.

Dr Richard Armer

Chief Scientific Officer

Experienced drug discovery executive, ex Pfizer, Organon

Richard Armer joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard’s expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.

Dr Jane Robertson

Chief Medical Officer

Experienced oncology drug developer ex. AstraZeneca, Achilles, Nucana. Led the successful clinical development of Lynparza

Prior to starting as Chief Medical Officer at Redx in March 2021,  Jane  was Chief Medical Officer at Achilles Therapeutics Ltd, a biotech company focused on the creation of a personalized T cell therapy directed against clonal tumour neoantigens. During her tenure at Achilles, the Company progressed its lead candidate into two clinical trials. Prior to Achilles, Jane served as the Chief Medical Officer at Nucana Biomed Ltd and at Kesios Therapeutics Ltd. She has previously also held a number of senior R&D leadership roles at AstraZeneca Oncology, notably leading the development of the first-in-class PARP inhibitor, Olaparib (Lynparza). Jane originally trained in general medicine and haematology, working in clinical practice and translational research settings, and sub-specialising in haemato-oncology; she remains General Medical Council registered.